Cingulate Has Completed Its Phase 3 Adult Dose-optimization Trial Of Its Lead Candidate, CTX-1301 (Dexmethylphenidate) For Attention Deficit/Hyperactivity Disorder; Results Are Expected In 3Q 2023
Portfolio Pulse from Benzinga Newsdesk
Cingulate has completed its Phase 3 adult dose-optimization trial for CTX-1301, a treatment for Attention Deficit/Hyperactivity Disorder (ADHD). Results are expected in 3Q 2023, with pivotal Phase 3 trials in pediatric/adolescent patients scheduled for initiation in the same quarter.
June 08, 2023 | 11:04 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cingulate's completion of the Phase 3 trial for CTX-1301 may positively impact its stock price, with results expected in 3Q 2023 and pediatric/adolescent trials scheduled for initiation in the same quarter.
The completion of the Phase 3 trial for CTX-1301 is a significant milestone for Cingulate, as it brings the company closer to potential FDA approval and commercialization of the drug. Positive results from the trial could lead to increased investor confidence and a higher stock price. The initiation of pediatric/adolescent trials in 3Q 2023 also demonstrates progress in the drug's development, which may further boost the stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100